Acromegaly Drug Trial now in 2nd Phase

The Australian pharmaceutical company Antisense Therapeutics Limited announced that they have recruited 24 patients into a trial for the acromegaly drug ATL 1103, and have completed the dosing regimen with two-thirds of the recruits. Thus far the company reports "positive" interim data for the injectable drug that aims to reduce levels of insulin-like growth factor 1 (IGF-1) in the blood. The results of the second phase will be reported this summer. Read more here.


Available Now!

PPRG6-500 Cover
The Pituitary Patient Resource Guide Sixth Edition is now available! Be one of the first to have the most up-to-date information. The Pituitary Patient Resource Guide a one of a kind publication intended as an invaluable source of information not only for patients but also their families, physicians, and all health care providers. It contains information on symptoms, proper testing, how to get a diagnosis, and the treatment options that are available. It also includes Pituitary Network Association's patient resource listings for expert medical care.

Buy Now